Michael Ryskin
BofA Securities, Research Division

[Audio Gap] Diagnostics team. And for our next session, we're joined by Revvity. Pleased to be joined by Steve Willoughby, Senior VP, Investor Relations, ESG and Risk. Steve, thanks for being here.

Stephen Willoughby
Senior VP of Investor Relations & Head of ESG

Thanks, Mike. Thanks for having me.

Michael Ryskin
BofA Securities, Research Division

Thanks for having a longer job title than I do. Maybe just to kick things off, maybe some opening high-level remarks on how the quarter played out relative to expectations, you just reported results a couple of weeks ago. A lot of things to dig in there, but maybe give us sort of like an overview to get us started.

Stephen Willoughby
Senior VP of Investor Relations & Head of ESG

Sure. Obviously, I think we had a pretty good quarter overall from both the top line perspective, margin perspective and obviously, bottom line, too. So we have started to see some early signs of some end market improvements. And I think maybe some of that could be a little bit more company specific to us for some reasons, which I'm sure we'll get into.

But overall, it was a good quarter, and I would say it progressed well throughout the quarter. Obviously, I would say the big news for us here in the first quarter, too, that we announced was the strategic decision to divest our immunodiagnostics business in China. I'm sure you have more questions on that as well, but that was a very key thing that we announced on the first quarter. And